相关实验视频
Updated: May 29, 2025

09:29
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
15.4K
抗治疗强迫症障碍中的布雷克西普拉增强:初步的回顾性观察性研究
Luca Giacovelli1, Eleonora Piccoli1, Paola Landi1
1Department of Biomedical and Clinical Sciences Luigi Sacco, Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
International clinical psychopharmacology
|February 5, 2025
概括
布雷克斯皮普拉对血清素再吸收抑制剂 (SRIs) 的增强显示出治疗耐药强迫症 (OCD) 的前景. 这项研究发现,70%的患者在12周内显著减少了症状,并出现了轻微的副作用.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床神经科学 临床神经科学
背景情况:
- 强迫症 (OCD) 是一种慢性精神健康状况,导致显著的功能障碍.
- 血清激素再吸收抑制剂 (SRIs) 是一线治疗,但许多患者只能获得部分症状缓解.
- 用抗精神病药物进行增强疗法是治疗耐药性强迫症的常见策略.
研究的目的:
- 评估布雷克斯皮普拉作为SRIs的附加治疗在治疗耐药性强迫症患者中的有效性和耐受性.
- 在12周的时间内使用耶鲁-布朗强迫症强迫性尺度 (Y-BOCS) 评估症状变化.
- 记录与布雷克斯皮普拉增强相关的任何不良事件.
主要方法:
- 一项追溯观察性研究,涉及10名被诊断患有耐治疗强迫症的患者.
- 患者在12周内接受了布雷克斯皮普拉 (brexpiprazole) 作为现有SRI治疗的补充剂,灵活的剂量从1毫克/天开始.
- 用Y-BOCS总分数的变化来衡量治疗反应,并系统地记录不良事件.
主要成果:
- 在12周后,强迫症症状显著改善.
- 70%的患者 (10人中有7人) 至少实现了Y-BOCS评分比基线下降25%.
- 50%的患者 (10人中有5人) 显示出更显著的反应,Y-BOCS得分降低≥35%.
- 20%的参与者报告了轻微的不良反应,包括镇静和体重增加.
结论:
- 布雷克西普拉对SRI的增强似乎是治疗耐药性强迫症的有效策略.
- 在这项初步研究中,该疗法显示出有前途的耐受性.
- 需要使用更大的样本大小进行进一步的研究来证实这些发现.
相关概念视频
Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103
Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
Obsessive-Compulsive Disorder
32
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...
32
Psychosis and Antipsychotic Drugs: Overview
171
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
171
Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
75
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
75

